Schwannoma News - LARVOL Sigma

Schwannoma

Welcome, Profile Billing Logout

29 Mechanisms of Action

||||||||||  dasatinib / Generic mfg.
Trial primary completion date, Metastases:  Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) -  Jun 19, 2014
P2, N=502, Active, not recruiting,  Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Dec 2013 --> Dec 2014

||||||||||  RG4733 / Roche
Enrollment change:  RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) -  May 29, 2014
P1, N=24, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2013 --> Dec 2014 N=34 --> 24

||||||||||  Endostar (recombinant human endostatin) / Simcere
New P2 trial:  Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (clinicaltrials.gov) -  Apr 2, 2014
P2, N=20, Recruiting,  Sponsor: Beijing Tiantan Hospital

||||||||||  Avastin (bevacizumab) / Roche
Trial completion:  Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) (clinicaltrials.gov) -  Mar 31, 2014
P2, N=14, Completed,  Sponsor: National Cancer Institute (NCI)
N=34 --> 24 Active, not recruiting --> Completed

||||||||||  cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases:  Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) -  Mar 18, 2014
P1, N=50, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=30 --> 50

||||||||||  Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy:  SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) -  Jan 15, 2014
P2, N=25, Active, not recruiting,  Sponsor: Sarcoma Alliance for Research through Collaboration
N=30 --> 50 Recruiting --> Active, not recruiting

||||||||||  Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Combination therapy:  Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) -  Nov 18, 2013
P1/2, N=61, Recruiting,  Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Suspended --> Recruiting

||||||||||  dacarbazine / Generic mfg., sorafenib / Generic mfg.
Trial completion:  Sorafenib and Dacarbazine in Soft Tissue Sarcoma (clinicaltrials.gov) -  Nov 12, 2013
P2, N=37, Completed,  Sponsor: Memorial Sloan-Kettering Cancer Center
Suspended --> Recruiting Active, not recruiting --> Completed

||||||||||  RG4733 / Roche
Enrollment closed:  RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) -  Mar 17, 2013
P1, N=24, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Metastases:  Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) -  Mar 10, 2013
P1, N=50, Active, not recruiting,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment open, Combination therapy, Metastases:  Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) -  Mar 3, 2013
P1b, N=120, Recruiting,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting

||||||||||  alisertib (MLN8237) / Puma
Enrollment open, Metastases:  Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) -  Nov 10, 2012
P2, N=135, Recruiting,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Suspended --> Recruiting

||||||||||  everolimus / Generic mfg.
Enrollment closed:  Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 (clinicaltrials.gov) -  Nov 8, 2012
P2, N=25, Active, not recruiting,  Sponsor: New York University School of Medicine
Suspended --> Recruiting Recruiting --> Active, not recruiting

||||||||||  alisertib (MLN8237) / Puma
Trial initiation date, Metastases:  Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) -  Aug 28, 2012
P2, N=135, Recruiting,  Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: Jan 2012 --> Aug 2012

||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Metastases:  Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) -  Aug 23, 2012
P2, N=74, Active, not recruiting,  Sponsor: Sarcoma Alliance for Research through Collaboration
Initiation date: Jan 2012 --> Aug 2012 Recruiting --> Active, not recruiting

||||||||||  Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy:  SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) -  Aug 7, 2012
P2, N=25, Active, not recruiting,  Sponsor: Sarcoma Alliance for Research through Collaboration

||||||||||  alisertib (MLN8237) / Puma
New P2 trial, Metastases:  Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) -  Jul 26, 2012
P2, N=135, Recruiting,  Sponsor: National Cancer Institute (NCI)

|||||||||| Trial completion: Recovery of Visual Acuity in People With Vestibular Deficits (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=98, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  emvododstat (PTC299) / PTC Therap
Trial suspension:  PTC299 for Treatment of Neurofibromatosis Type 2 (clinicaltrials.gov) -  Apr 5, 2012
P2, N=25, Suspended,  Sponsor: PTC Therapeutics
Active, not recruiting --> Completed Active, not recruiting --> Suspended

||||||||||  everolimus / Generic mfg.
Enrollment closed, Monotherapy:  AFINF2: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients (clinicaltrials.gov) -  Mar 15, 2012
P2, N=10, Active, not recruiting,  Sponsor: Assistance Publique - H
Active, not recruiting --> Suspended Recruiting --> Active, not recruiting

||||||||||  erlotinib / Generic mfg.
Trial completion, Metastases:  S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor (clinicaltrials.gov) -  Jan 16, 2012
P2, N=24, Completed,  Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  everolimus / Generic mfg.
New P2 trial, Monotherapy:  AFINF2: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients (clinicaltrials.gov) -  Dec 11, 2011
P2, N=10, Active, not recruiting,  Sponsor: Assistance Publique - H

||||||||||  everolimus / Generic mfg.
New P2 trial:  Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 (clinicaltrials.gov) -  Aug 16, 2011
P2, N=25, Active, not recruiting,  Sponsor: New York University School of Medicine

||||||||||  Votrient (pazopanib) / Novartis, BeiGene
New P1/2 trial, Combination therapy:  Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) -  Aug 14, 2011
P1/2, N=61, Recruiting,  Sponsor: Memorial Sloan-Kettering Cancer Center